Leflunomide Stada (Leflunomide)

Leflunomide works by inhibiting dihydroorotate dehydrogenase, an enzyme required for de novo pyrimidine synthesis. This inhibition limits the proliferation of activated T‑cells and other immune cells, thereby dampening the autoimmune response that drives inflammation and joint destruction in rheumatoid and psoriatic arthritis.

The dosage of Leflunomide Stada is individualized by the prescribing clinician based on the patient’s disease severity, response, and tolerability. The prescriber determines the appropriate starting dose, any loading regimen, and subsequent maintenance dose according to current clinical guidelines.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations. Women of child‑bearing potential must use effective contraception. Breastfeeding is not recommended while taking leflunomide, as the drug may be excreted in milk.

To order Leflunomide Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

The primary alternative to leflunomide in rheumatoid arthritis is methotrexate, another DMARD. While both suppress immune activity, leflunomide specifically targets pyrimidine synthesis, whereas methotrexate inhibits folate metabolism. Leflunomide may be preferred when patients cannot tolerate methotrexate’s hepatic or gastrointestinal side effects, but both require liver monitoring.

Leflunomide Stada tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the package is tightly closed to maintain stability throughout its shelf life.

Leflunomide Stada is administered orally as a tablet. Patients should swallow the tablet whole with a glass of water, preferably with food to reduce gastrointestinal discomfort. The exact timing and any loading dose are determined by the prescribing physician.

The most serious risks include liver toxicity (elevated enzymes or hepatitis), severe infections due to immunosuppression, pulmonary toxicity such as interstitial lung disease, and teratogenic effects that can cause fetal malformations. Patients should report any signs of jaundice, persistent cough, fever, or unexplained bruising to their healthcare provider promptly.

Leflunomide Stada should not be used by pregnant women, individuals with severe hepatic impairment, patients with active serious infections, or those with known hypersensitivity to leflunomide or any of its excipients. Caution is also advised in patients with compromised immune systems or pre‑existing lung disease.